Global sales in the fourth quarter were $15.6 billion, an increase of 7% compared to the fourth quarter of 2023; Excluding the impact of foreign exchange, the growth rate is 9%
GAAP earnings per share for the fourth quarter were $1.48; Non GAAP earnings per share of $1.72; Both GAAP and non GAAP earnings per share include an expense of $0.23 per share related to certain business development transactions
The global sales for the whole year were 64.2 billion US dollars, an increase of 7% compared to the whole year of 2023; If the impact of foreign exchange is excluded, the growth rate will be 10%
KEYTRUDA's sales increased by 18% to $29.5 billion; Excluding the impact of foreign exchange, sales increased by 22%
WINREVAIR's sales reached $419 million
Animal health sales increased by 4% to $5.9 billion; Excluding the impact of foreign exchange, sales increased by 8%
GARDASIL/GARDASIL 9 sales decreased by 3% to $8.6 billion; Excluding the impact of foreign exchange, sales decreased by 2%
GAAP earnings per share for the full year of 2024 were $6.74; Non GAAP earnings per share of $7.65; GAAP and non GAAP earnings per share include a net expense of $1.28 per share related to certain business development transactions
Fourth quarter:
Announcement of positive results in the critical Phase 3 trial of subcutaneous injection of pembrolizumab and Berahyaluronidase Alfa
The biological product approval application for Clesrovimab has been approved by the FDA. Clesrovimab is a long-acting monoclonal antibody under development, designed to protect infants from respiratory syncytial virus infection during the season of first respiratory syncytial virus infection
By signing exclusive global licenses for MK-2010 (an investigational anti-PD-1/VEGF bispecific antibody) with LaNova and MK-4082 (an investigational oral GLP-1 receptor agonist) with Hansoh, we have enhanced our diversified product line
In January 2025, GARDASIL was approved as a male vaccine in China
Financial Outlook for the Whole Year of 2025
Expected global sales will be between $64.1 billion and $65.6 billion
Expected non GAAP earnings per share range from $8.88 to $9.03; The outlook reflects a one-time fee of approximately $0.09 per share related to the expected milestone payment to LaNova